Douglas Carr is SVP Finance & Operations of Century Therapeutics, Inc.. Currently has a direct ownership of 334,041 shares of IPSC, which is worth approximately $384,147. The most recent transaction as insider was on Aug 05, 2024, when has been sold 289 shares (Common Stock) at a price of $1.83 per share, resulting in proceeds of $528. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 334K
0.09% 3M change
9.6% 12M change
Total Value Held $384,147

Douglas Carr Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 05 2024
SELL
Open market or private sale
$528 $1.83 p/Share
289 Reduced 0.09%
334,041 Common Stock
Jun 07 2024
BUY
Grant, award, or other acquisition
-
17,007 Added 4.84%
334,330 Common Stock
May 03 2024
SELL
Open market or private sale
$799 $3.11 p/Share
257 Reduced 0.08%
317,323 Common Stock
Mar 07 2024
BUY
Grant, award, or other acquisition
-
14,000 Added 4.22%
317,580 Common Stock
Feb 06 2024
SELL
Open market or private sale
$2,500 $4.49 p/Share
557 Reduced 0.18%
303,580 Common Stock
Feb 05 2024
SELL
Open market or private sale
$2,469 $3.84 p/Share
643 Reduced 0.21%
304,137 Common Stock
Nov 01 2023
SELL
Payment of exercise price or tax liability
$24,750 $1.49 p/Share
16,611 Reduced 5.17%
304,780 Common Stock
May 15 2023
BUY
Grant, award, or other acquisition
-
120,846 Added 27.33%
321,391 Common Stock
Feb 02 2023
BUY
Grant, award, or other acquisition
-
15,000 Added 6.96%
200,545 Common Stock
DC

Douglas Carr

SVP Finance & Operations
Philadelphia, PA

Track Institutional and Insider Activities on IPSC

Follow Century Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IPSC shares.

Notify only if

Insider Trading

Get notified when an Century Therapeutics, Inc. insider buys or sells IPSC shares.

Notify only if

News

Receive news related to Century Therapeutics, Inc.

Track Activities on IPSC